Abstract Number: 613 • 2013 ACR/ARHP Annual Meeting
The Influence Of Cumulative Dose Of Corticosteroids On The Presence Of Carotid Atherosclerosis In Patients With Longstanding Systemic Lupus Erythematosus
Background/Purpose: The purpose of this study is to determine the relationship between cumulative corticosteroid dose (CCD) with presence of carotid plaques (CP), total plaque area…Abstract Number: 615 • 2013 ACR/ARHP Annual Meeting
Relationship Between 25-Hydroxyvitamin D [25(OH)D] and Risk For Cardiovascular Events In Systemic Lupus Erythematosus Over 11 Years In An Inception Cohort
Background/Purpose: 25(OH)D deficiency has been associated with increased cardiovascular disease (CVD) in the general population. We investigated the relationship between 25(OH)D and CVD events in…Abstract Number: 616 • 2013 ACR/ARHP Annual Meeting
Trends Of Mortality Associated To Systemic Lupus Erythematosus At The Nation Level: A Multiple Cause-Of-Death Analysis In France
Background/Purpose: The overall mortality rate of Systemic Lupus Erythematosus (SLE) has improved significantly over the past 50 years but is still high as compared with…Abstract Number: 617 • 2013 ACR/ARHP Annual Meeting
The Potentiality Of Multi-Target Therapy With Cyclophosphamide and Tacrolimus For Lupus Nephritis
Background/Purpose: Multi-target therapy for lupus nephritis (LN) had first reported by Bao et al. 2008 regarding the treatment of mixed diffuse proliferative and membranous LN using…Abstract Number: 618 • 2013 ACR/ARHP Annual Meeting
Active Renal Disease Is Associated With The Presence Of The Metabolic Syndrome (MetS) In Peruvian Patients With Systemic Lupus Erythematosus (SLE)
Background/Purpose: The MetS prevalence is increased in SLE patients, in particular in those of Hispanic origin and it is associated with a higher risk for…Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…Abstract Number: 620 • 2013 ACR/ARHP Annual Meeting
Human Papillomavirus and Precancerous Lesions In Patients With Systemic Lupus Erythematosus
Background/Purpose: To evaluate the presence of Precancerous Lesions (PL) in uterine cervix in patients with Systemic Lupus Erythematosus (SLE) and its relationship with Human Papillomavirus…Abstract Number: 621 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics That Predict a Short-Term Response To Immunosuppressive Treatment In Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of devastating organ involvements in patients with connective tissue diseases (CTDs). Recent introduction of molecular-targeting PAH drugs, such…Abstract Number: 591 • 2013 ACR/ARHP Annual Meeting
Elevated Level Of cfDNA Mainly Derive From Netosis Of Common Neutrophils As Well As Low-Density Granulocytes In Systemic Lupus Erythematosus and Is Associated With Lupus Nephritis Severity
Background/Purpose: Insufficient clearance of neutrophil extracellular traps (NETs) has been involved in lupus nephritis and can cause the increase of residual NETs in vivo, which…Abstract Number: 598 • 2013 ACR/ARHP Annual Meeting
Gender Influence On Lupus Nephritis Outcomes In An Urban, Multiethnic Population
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease predominately of young women that disproportionately affects minorities. Lupus Nephritis (LN) causes major morbidity and mortality in…Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…Abstract Number: 583 • 2013 ACR/ARHP Annual Meeting
Prognostic Significance Of Visit-To-Visit Variability, Maximum Systolic Blood Pressure, and Episodic Hypertension In Sytemic Lupus Erythematosus
Background/Purpose: SLE is considered a coronary heart disease equivalent and aggressive management of all traditional risk factors is recommended. Hypertension is a major problem in…Abstract Number: 584 • 2013 ACR/ARHP Annual Meeting
The Effect Of Ramipril On Endothelial Function and Endothelial Progenitor Cells In Patients With Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular diseases (CVD) are one of major causes of morbidity and mortality in SLE patients. Traditional cardiovascular risk factors and disease intrinsic factors contribute…Abstract Number: 585 • 2013 ACR/ARHP Annual Meeting
Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?
Background/Purpose: There is an increase in cancer in SLE over-all, but decrease in other cancers, such as breast cancer. Of particular interest are autoantibodies targeting…Abstract Number: 586 • 2013 ACR/ARHP Annual Meeting
Blood Pressure Variability and Age-Related Blood Pressure Patterns In Systemic Lupus Erythematosus
Background/Purpose: Increased visit-to-visit blood pressure (BP) variability has been associated with an increased risk of all-cause mortality, stroke, left ventricular diastolic dysfunction, and cognitive impairment…